A Phase 1, Randomized, Placebo-controlled Safety, Tolerability and Pharmacokinetic Study of Single Ascending Doses of LMR-123 in Healthy Subjects
Latest Information Update: 28 Nov 2019
At a glance
- Drugs LMR 123 (Primary)
- Indications Stroke
- Focus Adverse reactions; First in man
Most Recent Events
- 26 Nov 2019 New trial record